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Cell death signalling pathways contribute to tissue homeostasis and provide innate protection from infection. Adaptor proteins such as receptor-interacting serine/threonine-protein kinase 1 (RIPK1), receptor-interacting serine/threonine-protein kinase 3 (RIPK3), TIR-domain-containing adapter-inducing interferon-β (TRIF) and Z-DNA-binding protein 1 (ZBP1)/DNA-dependent activator of IFN-regulatory factors (DAI) that contain receptorinteracting protein (RIP) homotypic interaction motifs (RHIM) play a key role in cell death and inflammatory signalling [1] [2] [3] . RHIM-dependent interactions help drive a caspase-independent form of cell death termed necroptosis 4, 5 . Here, we report that the bacterial pathogen enteropathogenic Escherichia coli (EPEC) uses the type III secretion system (T3SS) effector EspL to degrade the RHIM-containing proteins RIPK1, RIPK3, TRIF and ZBP1/DAI during infection. This requires a previously unrecognized tripartite cysteine protease motif in EspL (Cys47, His131, Asp153) that cleaves within the RHIM of these proteins. Bacterial infection and/or ectopic expression of EspL leads to rapid inactivation of RIPK1, RIPK3, TRIF and ZBP1/DAI and inhibition of tumour necrosis factor (TNF), lipopolysaccharide or polyinosinic:polycytidylic acid (poly(I:C))-induced necroptosis and inflammatory signalling. Furthermore, EPEC infection inhibits TNF-induced phosphorylation and plasma membrane localization of mixed lineage kinase domain-like pseudokinase (MLKL). In vivo, EspL cysteine protease activity contributes to persistent colonization of mice by the EPEC-like mouse pathogen Citrobacter rodentium. The activity of EspL defines a family of T3SS cysteine protease effectors found in a range of bacteria and reveals a mechanism by which gastrointestinal pathogens directly target RHIM-dependent inflammatory and necroptotic signalling pathways.
RHIM-containing proteins, including RIPK1, RIPK3, TRIF and ZBP1/DAI, play essential roles in the regulation of inflammatory and cell-death-signalling pathways 5 . RIPK1 is a key regulator of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling pathway in response to TNF/tumour necrosis factor receptor 1 (TNFR1) stimulation and may induce apoptosis through formation of a cytosolic complex containing tumour necrosis factor receptor 1-associated DEATH domain protein (TRADD)/ fas-associated death domain protein (FADD) and caspase-8 (ref. 6 ). However, upon inhibition of caspase-8 activity, RIPK1 binds RIPK3 through RHIM-RHIM interactions, leading to phosphorylation of RIPK3 and the recruitment and phosphorylation of MLKL by activated RIPK3 (refs 7-11) . Phosphorylated oligomeric MLKL translocates to the plasma membrane, which leads to the caspaseindependent form of cell death termed necroptosis 12, 13 . Necroptosis may also result from TRIF or ZBP1/DAI interactions with RIPK1 and RIPK3, which are also mediated by RHIM-RHIM interactions 14, 15 . In addition, RIPK3 can promote NLRP3 inflammasome activation independently of necroptosis, which is thought to be triggered by RHIM-RHIM amyloid formation 16 . Infection of intestinal epithelial cells with the attaching and effacing enteropathogenic Escherichia coli (EPEC) leads to rapid inhibition of host inflammatory and apoptosis signalling pathways due to the activity of T3SS effectors 17 . While studying the effect of EPEC infection on assembly of the TNFR1 receptor complex, we observed that RIPK1 was rapidly degraded during wild-type EPEC infection (E2348-69), but not during infection with the T3SS mutant (ΔescN) (Supplementary Fig. 1a ). By testing derivatives of EPEC lacking the genomic islands PP4 alone (ΔPP4) or PP4 and IE6 (ΔPP4-IE6), we identified IE6 and subsequently the gene encoding the effector EspL as essential for T3SS-dependent RIPK1 degradation ( Fig. 1a and Supplementary  Fig. 1b) . espL is located upstream of the T3SS effector genes nleB1 and and nleE, which encode known inhibitors of apoptosis and NF-κB activation, respectively (Fig. 1a ) [18] [19] [20] . We confirmed that EspL was translocated by the T3SS using the TEM1 β-lactamase reporter 21 and that deletion of espL had no impact on actin accretion by EPEC, a measure of adherence and T3SS activity ( Supplementary Fig. 1c-e) . ( p E s p L ) In mammalian cells, RIPK1 may be removed by K48-linked ubiquitylation and proteosomal degradation or by caspase-mediated cleavage [22] [23] [24] . However, neither caspase nor proteasome inhibitors z-VAD-FMK (z-VAD) and MG132, respectively, prevented EspLdependent loss of RIPK1 (Fig. 1b) . Therefore, we speculated that EspL might mediate direct degradation of RIPK1. Although amino acid sequence analysis failed to uncover any canonical protease motifs, alignment of EspL with homologues identified by BLAST (ref. 25 ) from a range of bacterial pathogens revealed a putative conserved cysteine protease motif with possible catalytic residues Cys47, His131 and Asp153 (Figs 1c,d, 2a and Supplementary  Fig. 2 ). Despite lacking primary amino acid sequence similarity with known cysteine proteases, the secondary structure of EspL predicted by Phyre 26 showed N-terminal similarity to the CA clan of papain-like cysteine proteases, which includes the unrelated T3SS effector YopT from Yersinia spp. (Fig. 1c ) 27 . Despite this, the broad-spectrum cysteine protease inhibitors, antipain and Z-FA-FMK, had no or only a weak effect on EspL activity ( Supplementary Fig. 1f ). Complementation of EPEC strain ΔPP4-IE6 or the ΔespL mutant with native EspL expressed in trans restored RIPK1 degradation. However, alanine substitution of Cys47, His131 and Asp153, but not Cys40, abrogated EspLinduced RIPK1 degradation, confirming the crucial role of these amino acids in EspL activity (Fig. 1d) .
To determine the specificity of EspL for RIPK1 degradation, we examined the effect of EPEC infection on human as well as murine RIP kinases by immunoblot. In addition to RIPK1, catalytically active EspL also induced loss of RIPK3, which shares a high degree of similarity with RIPK1 28 ( Fig. 1d and Supplementary  Fig. 3a) . Levels of RIPK2 were unaffected by EspL. Using an antibody generated to residues 385-650 of RIPK1, we detected a ∼14 kDa cleavage product following ectopic expression of codon optimized Flag-EspL in HEK293T cells, suggesting that EspL removed the C terminus of RIPK1, which encompasses the RHIM ( Supplementary Fig. 3b ). To test the ability of EspL to cleave directly all mammalian RHIM-containing proteins, we incubated purified recombinant EspL with the purified RHIM-containing regions of RIPK1, RIPK3, TRIF and ZBP1 and observed cleavage by catalytically active EspL for all RHIM proteins (Fig. 2b) . Intact mass spectrometry and N-terminal sequencing of the cleavage products from RIPK3 and TRIF identified the cleavage site as QxGxx↓N (P5-P4-P3-P2-P1-P1′) (Fig. 2b,c and Supplementary Fig. 3c,d ). Δ P P 4 -IE
( p N l e B 1 ) Representative immunoblot from at least three independent experiments. GAPDH: cytosolic fraction loading control; VDAC: membrane fraction loading control.
Substitution of V 448 , Q
449
, I 450 and G 451 with alanine abrogated the ability of EspL to cleave RIPK3 during EPEC infection, suggesting that this conserved RHIM sequence was important for substrate recognition by EspL ( Supplementary Fig. 3e ). EspL also possessed the ability to cleave the viral RHIM-containing protein M45 from murine cytomegalovirus (MCMV) ( Supplementary Fig. 3f ).
Given the observed cleavage of RIPK1 and RIPK3, we hypothesized that EspL would prevent RIPK1/RIPK3-dependent necroptosis. Mouse dermal fibroblasts (MDFs) were used to create stable, doxycycline-inducible cell lines expressing EspL or EspL C47S . Induction of catalytically active EspL was coincident with loss of RIPK1 and RIPK3, and this effect was reversible following the removal of induction ( Supplementary Fig. 4a,b) . Cells expressing EspL were protected from necroptotic cell death, as measured by propidium iodide (PI) uptake, when induced by treatment with TNF, QVD or z-VAD (as caspase inhibitors) and the Smac-mimetic IAP antagonist, compound A (Cp.A) as an inhibitor of NF-κB activation 29 . These conditions are known to induce cell death by necroptosis 13 . This protection required EspL activity ( Supplementary Figs 4c and 5a,b) . EspL expression in MDF cells Induced + poly(I:C) also prevented MLKL oligomerization and membrane translocation ( Supplementary Fig. 5c ), two hallmarks of necroptosis 13 . During infection, EPEC blocked MLKL phosphorylation, oligomerization and membrane translocation and consequently necroptosis in HT-29 cells in an EspL dependent manner ( Fig. 3 and Supplementary Fig. 6 ).
Apart from EspL, the T3SS effector NleB1 from EPEC can block TNF-induced necroptosis by modifying a conserved arginine in the death domain of RIPK1 with N-acetyl glucosamine (GlcNAc) 19 . Consistent with partial redundancy in EspL and NleB1 function, only EPEC derivatives lacking both espL and nleB1 (ΔPP4-IE6 or ΔespLnleBE) were unable to inhibit TNF-induced necroptosis ( Fig. 3b and Supplementary Fig. 6 ). In addition, complementation of ΔPP4-IE6 with either active EspL or NleB, but not NleE, restored EPEC-mediated inhibition of necroptosis, whereas inactive EspL (EspL C47S ) or NleB1 (NleB1 AAA ) 18, 19 did not ( Fig. 3 and Supplementary Fig. 6 ).
Consistent with loss of RIPK1, ectopic expression of EspL, but not inactive EspL, blocked TNF-induced expression of an NF-κB-dependent luciferase reporter ( Supplementary Fig. 7a ). In addition, EspL delivered by the T3SS in the EPEC mutant background ΔPP4-IE6 resulted in reduced IL-8 production by infected HT-29 cells (Supplementary Fig. 7b ). EspL-dependent loss of TRIF following EPEC infection or ectopic expression resulted in impaired interferon-β (Infβ) expression and necroptosis induced by the TLR3 and TLR4 ligands, poly(I:C) and LPS, respectively (Fig. 4a,b and Supplementary Fig. 7c ). Using immortalized bone marrow derived macrophages (iBMDMs), we observed that EspL blocked NLRP3/RIPK3-dependent caspase-1 activation induced by treatment with Cp.A/QVD (ref. 16) , whereas activation of the canonical NLRP3 inflammasome by nigericin was unaffected ( Supplementary Fig. 7d ).
Although EspL possessed the ability to cleave all mammalian RHIM-containing proteins, a time course comparing RIPK1 and RIPK3 cleavage suggested that RIPK1 was the preferred target during EPEC infection ( Supplementary Fig. 8a ). In addition, cleavage probably occurred before amyloid formation as RHIM fibrils were only inefficiently cleaved by EspL compared to the monomeric proteins ( Supplementary Fig. 8b,c) . Amyloid fibrils form the signalling scaffold of the necrosome and arise from RHIM-RHIM interactions between RIPK1 and RIPK3 (ref. 4) .
The targeted inhibition of necroptosis and RHIM-dependent inflammatory signalling by EspL during EPEC infection suggested that the activity of EspL might aid mucosal immune evasion. We assessed the ability of derivatives of the EPEC-like mouse pathogen, Citrobacter rodentium, to colonize wild-type C57BL/6 mice. C. rodentium is a murine attaching and effacing pathogen that carries all the conserved T3SS effector genes present in EPEC, including espL. We confirmed that EspL from C. rodentium (CREspL) cleaved RIPK1, whereas inactive CREspL C42S did not (Fig. 4c) . In wild-type C57BL/6 mice, we observed that an espL mutant of C. rodentium was attenuated for intestinal colonization in the resolving phase of infection, suggesting that EspL promoted bacterial persistence in the gut, similar to previous findings 30 ( Supplementary  Fig. 9 ). Complementation of the espL mutant with espL but not espL C47S restored intestinal colonization by C. rodentium (Fig. 4d) , suggesting that the cysteine protease activity of EspL was critical to its virulence function. Given the semi-redundant activities of EspL and NleB1 that we observed in the inhibition of necroptosis and the fact that nleB mutants of C. rodentium also exhibit a colonization defect 18, 19 , further work should examine the relative contribution of each effector in vivo using an espL/nleB double mutant of C. rodentium complemented with active and inactive forms of NleB and EspL.
Here, we have defined EspL from EPEC as the prototypic member of a family of T3SS cysteine protease effectors and identified the targets of EspL as host RHIM-containing proteins. EspL inactivated inflammatory, inflammasome and necroptotic signalling by cleaving within the RHIM, thereby disrupting a range of host mucosal defence pathways. EspL adds to the arsenal of bacterial T3SS effectors that subvert host cell signaling, and the presence of (as yet uncharacterized) EspL homologues in a broad range of bacterial pathogens suggests that this family of cysteine protease effectors constitutes a widespread virulence mechanism.
Methods
Bacterial strains, plasmids, cell lines and growth conditions. The bacterial strains, plasmids and oligonucleotide primers used in this study are listed in Supplementary  Table 1 . Bacteria were grown at 37°C in Luria-Bertani (LB) medium, Dulbecco's modified Eagle's medium (DMEM) with GlutaMAX (Gibco), or Roswell Park Memorial Institute medium (RPMI) with GlutaMAX (Gibco) where indicated, and supplemented with ampicillin (100 µg ml -1 ), kanamycin (100 µg ml -1 ), nalidixic acid (50 µg ml -1 ) or chloramphenicol (25 µg ml -1 ), where necessary. MDFs were isolated from the dermis of adult mice and immortalized with SV40 large T antigen 31 . BMDMs from C57BL/6 mice were immortalized to generate a macrophage cell line (iBMDMs) with CreJ2 virus as described previously 32 . All other cell lines were sourced from and authenticated by either the ATCC Global Bioresource Centre, or the ECACC via Sigma-Aldrich. HeLa cells, HEK293T cells, Caco-2 cells, iBMDMs and MDFs were grown in DMEM GlutaMax (Gibco) supplemented with 10% FCS (Sigma) at 37°C with 5% CO 2 . HT-29 cells were grown in RPMI, GlutaMAX (Gibco) with 10% FCS (Sigma) at 37°C with 5% CO 2 .
Construction of EspL expression vectors. For expression in bacteria, the espL gene was amplified from EPEC E2348/69 genomic DNA by PCR using the primer pair EspL F /EspL R for cloning into pTrc99A. PCR amplification consisted of an initial denaturation step at 95°C for 10 min, followed by 30 cycles of 94°C for 44 s, 55°C for 45 s and 70°C for 2 min followed by a final elongation step of 70°C for 10 min. The PCR product was digested with KpnI and EcoRI and ligated into pTrc99A to produce pEspL.
For expression in mammalian cells, the gene encoding EspL from either EPEC E2348/69 or C. rodentium ICC169 was codon-optimized (DNA2.0), amplified using the primer pair EspL COF /EspL COR or EspL CRCOF /EspL CRCOR , and ligated into KpnI/BamHI digested p3XFlag-Myc-CMV-24 to generate N-terminal 3xFlag fusions of EspL (pFlag-EspL or pFlag-CREspL). For construction of the lentiviral plasmid to generate stable inducible cell lines, codon-optimized Flag-EspL was amplified from pFlag-EspL and ligated into pF TRE3G PGK puro 10,29 using BamHI/XbaI.
Genes encoding residues 2-549 of EPEC E2348/68 EspL and EspL C47S were amplified by PCR using pEspL and pEspL C47S as template DNA, respectively, using the primer pair EspL GEXF /EspL GEXR . PCR products were digested with BamHI and NotI and ligated into the vector pGEX-2T-TEV, as previously described 33 to enable bacterial expression with an in-frame N-terminal glutathione S-transferase (GST) fusion. Insert sequences were verified by Sanger sequencing (Micromon, Monash University).
Site-directed mutagenesis. Site-directed mutants were generated using the Stratagene QuikChange II Site-Directed Mutagenesis Kit according to the manufacturer's protocol. pEspL C40S , pEspL C47S , pEspL H131A and pEspL D153A were generated using pEspL as template DNA and primer pairs EspL (C40S)F /EspL (C40S)R , EspL (C47S)F /EspL (C47S)R , EspL (H131A)F /EspL (H131A)R and EspL (D153A)F /EspL (D153A)R , respectively. pFlag-EspL C40S , pFlag-EspL C47S , pFlag-EspL H131A and pFlagEspL D153A were generated using pFlag-EspL as template DNA and primer pairs EspL (C40S)COF /EspL (C40S)COR , EspL (C47S)COF /EspL (C47S)COR , EspL (H131A)COF / EspL (H131A)COR and EspL (D153A)COF /EspL (D153A)COR , respectively. pF TREGFlag-EspL C47S was generated using pF TREG-Flag-EspL as template DNA and primer pair EspL (C47S)COF /EspL (C47S)COR . pFlag-CREspL C42S was generated using pFlag-CREspL as template DNA and primer pair EspL C42S(CO)F /EspL C42S(CO)R . pGEX-EspL C47S was generated by PCR-amplification of a cDNA encoding EPEC E2348/69 EspL C47S (pTrc-EspL C47S ) using primers EspL GEXF /EspL GEXR bearing restriction sites (5′ BamHI, 3′ NotI), followed by restriction digest and ligation into the vector, pGEX-2T-TEV (pGEX-EspL C47S ). pGFP-mRIPK3 AAAA was generated using pGFP-mRIPK3 as template DNA and primer pair mRIPK3 AAAA-F /mRIPK3 AAAA-R .
Purification of GST-EspL. Super broth cultures (600 ml) containing 100 µg ml -1 ampicillin were inoculated with E. coli BL21 Codon Plus transformed with GST-EspL or GST-EspL C47S expression constructs and cultured at 37°C with shaking to an optical density at 600 nm (OD 600 ) of 0.6-0.8. Cultures were then cooled to 18°C, protein expression induced by addition of 1 mM isopropyl-β-D-thiogalactoside (IPTG) with continued shaking and incubation at 18°C overnight. Cell pellets were resuspended in lysis buffer (200 mM NaCl, 20 mM HEPES pH 7.5, 5% wt/vol glycerol, 0.5 mM tris (2-carboxyethyl) phosphine, before lysis by sonication, elimination of debris by centrifugation at 45,000g, 0.45 µm filtration of the lysate and incubation with glutathione agarose (UBP Bio) at 4°C with agitation for 1-2 h. Beads were collected and washed with lysis buffer before incubation with 200 µg TEV protease at 20°C for 2 h on rollers. Supernatant containing cleaved EspL or EspL C47S was concentrated by centrifugal ultrafiltration and loaded onto a Superdex S200 gel filtration column pre-equilibrated with gel filtration buffer (200 mM NaCl, 20 mM HEPES pH 7.5, 5% vol/vol glycerol). Fractions containing purified EspL or EspL C47S , as assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), were pooled, concentrated by centrifugal ultrafiltration to 5 mg ml -1 , aliquoted, snap-frozen in liquid nitrogen, and stored at -80°C until required.
RHIM domain protein constructs, expression and purification. Synthetic genes encoding RHIM-containing regions of human RIPK1 (Q13546; residues 497-583), human RIPK3 (Q9Y572; residues 387-518), human ZBP1/DAI (Q9H171; residues 170-429), human TRIF (Q8IUC6; residues 601-712) with flanking BamHI and EcoRI restriction sites were purchased from Genscript, digested with restriction enzymes, purified by agarose gel electrophoresis and ligated individually into the pHUE vector cut with the same two restriction enzymes 34 . All expressed fusion proteins therefore consist of a His6-ubiquitin-RHIM region. Successful cloning was confirmed by sequencing at AGRF (Westmead Institute) Sydney. Proteins were expressed in BL21(DE3) grown at 37°C to an OD 600 of 0.6-0.8, and induced with 0.5 mM IPTG for 3 h. Cell pellets were lysed in 6 M GuHCl, 100 mM NaH 2 PO 4 , 20 mM Tris.Cl, 5 mM β-mercaptoethanol, pH 8.0, and soluble material further purified on Ni-NTA agarose under denaturing conditions, with exchange into 8 M urea, 100 mM NaH 2 PO 4 , 20 mM Tris, 5 mM β-mercaptoethanol at pH 6.0 for washing and pH 4.0 for elution from the Ni-NTA agarose.
Generation of stable inducible cell lines in MDFs and iBMDMs. HEK293T cells were seeded at 2 × 10 5 cells per 10 cm culture dishes and 24 h later were cotransfected with 10 µg of either pF TRE3G-Flag-EspL or pF TRE3G-Flag-EspL C47S along with the helper plasmids pMDL-RRE, pRSV-REV and pVSV-g (5, 2.5 and 3 µg, respectively) using Effectine Transfection Reagent (Qiagen) for a further 24 h. Culture media were then changed and the cells were incubated for a further 48 h for virus production. Polybrene (5 µg ml -1 ; Sigma) was added to the cell culture dishes and the virus-containing supernatant was collected and passed through a 0.45 µM filter. Virus-containing supernatant was added to either MDF monolayers or iBMDM monolayers and incubated at 37°C with 5% CO 2 for 24 h. Infected cells were selected for using increasing concentrations of up to 5 µg ml -1 of puromycin (Sigma) for at least one week. Expression of Flag-EspL or Flag-EspL C47S in either MDFs or iBMDMs was tested by adding 20 ng ml -1 doxycycline at varying time points followed by immunoblot using anti-Flag antibodies.
Construction of C. rodentium espL mutant. A 325 bp upstream region of espL was amplified using primer pair Up-EspL-Fw/BamHI-Up-EspL-Rv, and a 500 bp downstream region of espL was amplified using primer pair BamHI-DownEspL-Fw/Down-EspL-Rv. Both fragments were then digested with BamHI, ligated together and cloned into pGEMT. The nonpolar aphT cassette 35 was then inserted into the BamHI site between the two fragments and the orientation of the aphT cassette ascertained by PCR. This construct was then amplified using the primer pair Up-EspL-Fw/Down-EspL-Rv. The PCR products were electroporated into ICC169 containing pKD46 encoding lambda red recombinase 36 . Transformants were selected on kanamycin agar plates and espL deletion confirmed by PCR (Check-EspL-UP-Fw/Down-EspL-Rv) and DNA sequencing.
Cis complementation of the C. rodentium espL mutant. The C. rodentium espL mutant was cis complemented with either wild-type espL or espL C42S using the transgene insertion method described previously 37 . Briefly, the espL gene with its native promoter was amplified from a C. rodentium ICC169 genomic DNA template by PCR using primers EspL CRF1 /EspL CRR1 and then ligated into the XmaI/XhoI restriction sites of the pGRG36 vector. The pGRG36-EspL C42S construct was generated by site-directed mutagenesis. The pGRG36-EspL construct was used as template DNA and amplified by PCR using primers EspL C42SF /EspL C42SR . The resulting plasmid was digested with DpnI at 37°C overnight before transformation into the appropriate E. coli strain.
The pGRG36-EspL and pGRG36-EspL C42S constructs were confirmed by PCR using primers Tn7 F /Tn7 R , then electroporated into electrocompetent C. rodentium espL mutant cells and selected for using 100 µg ml -1 ampicillin and incubated at 30°C overnight. Transformants were streaked out once, then grown overnight in LB without antibiotics at 30°C. Dilutions were prepared and plated on LB and grown overnight at 42°C. Transposition of the Tn7:espL/espL C42S into the attTn7 insertion site in the C. rodentium espL mutant chromosome was confirmed by the absence of the ampicillin resistance marker and PCR using primers CRseq F /CRseq R .
Construction of EPEC single and triple deletion mutants. To construct the EPEC E2348/69 espL deletion mutant strain, 342 bp and 331 bp fragments were amplified from 5′ and 3′ flanking sites of espL using oligonucleotides EspL 5′F / EspL 5′R and EspL 3′F /EspL 3′R . Plasmid pKD4 was used as template DNA to amplify the kanamycin cassette using oligonucleotides pKD3-4 F and pKD3-4 R . Overlapping PCR was used to assemble the espL flanking regions with the kanamycin cassette construct using oligonucleotides EspL 5′F and EspL 3′R . Lambda-red-mediated recombination 36 was used to replace the wild-type allele with the kanamycin resistance cassette. The cassette was electroporated into wild-type EPEC E2348/69 and positive clones were selected for on LB agar with 25 µg ml -1 kanamycin. To construct the EPEC E2348/69 espLnleBE deletion mutant, a 368 bp fragment was amplified from the 5′ flanking site of nleB using oligonucleotides NleB 5′F / NleB 5′R and a 550 bp fragment was amplified from the 3′ flanking site of nleE using oligonucleotides NleE 3′F / NleE 3′R . The plasmid pKD3 was used as template DNA to amplify the chloramphenicol cassette using oligonucleotides pKD3-4 F and pKD3-4 R . Overlapping PCR was used to assemble the nleB and nleE flanking regions with the chloramphenicol cassette construct using oligonucleotides NleB 5′F and NleE 3′R . Lambda-red-mediated recombination 36 was used to replace the wildtype allele with the chloramphenicol resistance cassette. The cassette was electroporated into EPEC E2348/69 espL mutant cells and positive clones were selected for on LB agar with 5 µg ml -1 chloramphenicol. Deletions were confirmed by PCR with a combination of primers from outside and inside the altered region. Attachment and pedestal formation by parental and mutant strains were confirmed using fluorescence actin staining.
EPEC infection. Cell lines of HeLa, Caco-2, MDF and HT-29 cells are maintained in our laboratory and regularly tested for mycoplasma contamination. Two days before infection, HeLa, Caco-2, MDF or HT-29 cell monolayers were seeded into 24-well tissue culture trays. One day before infection, derivatives of EPEC were inoculated into LB broth and grown with shaking at 37°C overnight. On the day of infection, overnight cultures of EPEC were sub-cultured 1:75 in DMEM GlutaMAX (Gibco) or RPMI GlutaMAX (Gibco) and grown statically for 3 h at 37°C with 5% CO 2 . Where necessary, cells were induced with 1 mM IPTG (Sigma) 30 min before infection. Cells were washed twice with PBS and infected with EPEC grown to an OD 600nm of 0.03 for 1-3 h (depending on the experiment). When required, the inhibitors MG132 (Sigma) (10 µM), antipain (Sigma; 10, 20 or 40 µg ml Transfection. All transfections were performed in HEK293T cells using Fugene 6 (Promega) transfection reagent. Cells were seeded into 24-well tissue culture trays and transfected 24 h later with 1 µg DNA for a period of ∼18 h.
Fluorescent actin stain. HeLa cells were seeded on coverslips and infected as previously described. After infection, cells were washed with PBS, fixed in 4% PFA in PBS for 30 min and permeabilized in 1% Triton X-100 for another 30 min. Cells were then washed twice with PBS and stained with 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen) at 0.5 mg ml -1 and phalloidin-tetramethylrhodamine B isothiocyanate (Sigma) in 3% BSA/PBS for 30 min. Coverslips were mounted onto microscope slides with Prolong Gold anti-fade reagent (Invitrogen). Images were acquired using a Zeiss confocal laser scanning microscope with a 1003/EC EpiplanApochromat oil immersion objective.
Immunoblot analysis. For immunoblot analysis following EPEC infection, transfection or induction of stable cell lines, cells were collected and lysed in cold lysis buffer (1% Triton X-100, 50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl) with Complete Protease Inhibitor (Roche), 2 mM Na 3 VO 4 , 10 mM NaF and 1 mM PMSF, and incubated on ice for 10 min to complete lysis. Samples were then pelleted at 4°C by centrifugation and the supernatants added to 4×Bolt LDS Sample Buffer (Thermo Fisher), heated to 70°C for 10 min, and resolved on Bolt 4-12% BisTris Plus Gels (Thermo Fisher) by PAGE. Proteins were transferred to nitrocellulose membranes using an iBlot2 Gel Transfer Device (Thermo Fisher) and probed with one of the following primary antibodies: mouse monoclonal anti-RIPK1 (38/RIP; BD Transduction Laboratories), mouse monoclonal anti-RIPK2/RICK (25/RIG-G; BD Transduction Laboratories), rabbit polyclonal anti-RIPK3 (Abcam; for HT-29 cells), rabbit polyclonal anti-RIPK3 (ProSci; for MDF cells) or rabbit polyclonal anti-TRIF (Cell Signaling), mouse monoclonal anti-Flag M2-HRP (Sigma), mouse monoclonal anti-GFP (7.1 and 13.1; Roche), mouse monoclonal anti-β-actin (AC-15; Sigma), mouse monoclonal anti-TRADD (7G8; Cell Signaling), rabbit polyclonal anti-TRAF2 (Cell Signaling), monoclonal rat anti-mouse MLKL (WEHI-3H1; WEHI, made in-house), mouse monoclonal anti-TEM1 β-lactamase (8A5.A10; QED Bioscience) diluted in TBS with 5% BSA (Sigma) and 0.1% Tween (Sigma). Proteins were detected using anti-rabbit or anti-mouse IgG secondary antibodies conjugated to horseradish peroxidase (PerkinElmer) diluted in TBS with 5% BSA (Roche) and 0.1% Tween (Sigma) and developed with enhanced chemiluminescence (ECL) western blotting reagent (Amersham). Images were visualized using an MFChemiBis imaging station (DNR). At least three biological replicates were performed for all experiments.
Cell viability assays (MTT and PI staining). For analysis of cell viability using MTT assays, iBMDMs stably expressing either EspL or EspL C47S were seeded into 24-well tissue culture plates (Corning) for 18-24 h before being left untreated or treated with 20 ng ml -1 of LPS (E. coli 0111:B4; Sigma) or 50 µg ml -1 poly(I:C) (for iBMDMs; Sigma) or 10 µg ml -1 high-molecular-weight poly(I:C) (InvivoGen) and 10 µM z-VAD-FMK (Abcam) for a further 18 h. The cells were washed once with PBS and replaced with DMEM containing 0.1 µg ml -1 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) for 1 h, after which the medium was removed and 100 µl of DMSO (Sigma) was added to each well. After thorough mixing on an orbital shaker for 1 min, the absorbance at 540 nm for each well was obtained using a CLARIOstar microplate reader (BMG Labtech). Results were obtained from at least three independent experiments.
For analysis of cell viability by PI staining of HT-29 monolayers, cells were seeded into 24-well tissue culture plates with sterile glass coverslips; 48 h later they were infected with EPEC derivatives (as previously mentioned) for 2.5 h, followed by 4 h incubation in media supplemented with 50 µg ml -1 gentamicin and 20 ng ml -1 TNF (Calbiochem), 500 nM Cp.A (Tetralogic), 25 µM z-VAD-FMK (Abcam). PI (50 µg ml -1 ; Sigma) was added for the final 15 min of treatment. Cells were then fixed in 3.7% (wt/vol) formaldehyde (Sigma) in PBS for 10 min and permeabilized with 0.2% Triton (Sigma) for 4 min. DAPI (Invitrogen) was applied at 0.5 µg ml -1 in PBS for 10 min. Cells were washed with PBS three times, and coverslips were mounted onto microscope slides with Prolong Gold anti-fade reagent (Invitrogen). Images were acquired using a Zeiss confocal laser-scanning microscope with a ×100/EC Epiplan-Apochromat oil immersion objective. Duplicate coverslips were blinded for counting of PI-positive cells and results were obtained from at least three independent experiments.
For analysis of cell viability by PI staining and confocal microscopy in MDF cells, EspL-and EspL C47S -expressing lines were induced with 20 ng ml -1 doxycycline for 2 h followed by 4 h incubation in media supplemented with 20 ng ml -1 TNF, 500 nM Cp.A, 25 µM z-VAD-FMK. PI, DAPI staining and confocal microscopy were carried out as described above. Duplicate coverslips were blinded for counting of PI-positive cells and results were obtained from at least three independent experiments.
For analysis of cell viability by PI staining and flow cytometry, MDF-EspL and MDF-EspL C47S , cell lines were induced with 10 ng ml -1 doxycycline for 1 h followed by 24 h incubation in media supplemented with 100 ng ml -1 hTNF-Fc produced in house (WEHI), 500 nM Cp.A and 50 µM QVD-OPH (Abcam). Cell death was assessed with PI staining (1 µg ml -1 ) and quantified using a BD FACSCalibur flow cytometer. Data was analysed using the WEASEL Flow Cytometry Software.
Monitoring MLKL complex formation using Blue native (BN)-PAGE. For MDF cells, 5 × 10 5 cells (wild-type, stably expressing inducible Flag-EspL or FlagEspL C47S ) were used to seed each well of a six-well tissue culture plate and allowed to attach overnight. Cells were stimulated with 0.5 µg ml -1 doxycycline for 2 h to induce Flag-EspL expression before the addition of 100 ng ml -1 hTNF-Fc produced in house (WEHI), 500 nM Cp.A, 25 µM z-VAD-FMK for a further 4 h to induce necroptosis. For HT29 cells, 5 × 10 5 cells were plated in each well of a six-well plate and allowed to attach for 48 h. Cells were infected with derivatives of EPEC E2348/69 for 2.5 h followed by stimulation with 20 ng ml -1 TNF, 500 nM Cp.A, 25 µM z-VAD-FMK for a further 5 h to induce necroptosis. Cells were collected by scraping and permeabilized in MELB buffer (20 mM HEPES (pH 7.5), 100 mM KCl, 2.5 mM MgCl 2 , 100 mM sucrose, 0.025% digitonin (Biosynth) 2 µM N-ethyl maleimide, complete protease inhibitor (Roche) and PhosSTOP phosphatase inhibitor cocktail (Roche)). Cytosolic and crude membrane fractions were separated by centrifugation, and the crude membrane fraction was further solubilized in MELB buffer containing 1% digitonin and clarified by centrifugation. Digitonin was added to the cytosolic fraction (final 1% wt/vol) and fractions were resolved on a 4-16% bis-tris native PAGE gels (Thermo Fisher), transferred to PVDF and probed for rabbit anti-human phospho-MLKL (Abcam), monoclonal rat anti-mouse MLKL (WEHI-3H1) (WEHI, made in house), rabbit polyclonal anti-VDAC1 (Millipore) and rabbit polyclonal anti-GAPDH (Cell Signaling).
Inflammasome activation. iBMDMs (WT, EspL or EspL C47S ) were seeded in 12-well tissue culture treated plates and treated with 50 ng ml -1 ultra-pure LPS (Invivogen) for 2 h then 1 µg ml -1 doxycycline (Sigma) was added for an additional 2 h. Cells were subsequently stimulated with 1 µM Cp.A and/or 15 µM QVD-Oph (RnD Systems) for 6 h or 10 µM nigericin (Sigma) for 1 h. Cell supernatants and lysates were analysed by western blot. Primary antibodies used were mouse monoclonal anti-Flag M2-HRP (Sigma), mouse monoclonal caspase-1 (casper-1) (Adipogen), mouse monoclonal anti-RIPK1 (38/RIP; BD Transduction), rabbit polyclonal RIPK3 (Axxora; PSC-2283-C100) and mouse monoclonal anti-β-actin (AC-15; Sigma). All antibody dilutions were performed in 5% skimmed milk/0.1% PBS Tween.
IL-8 secretion assay. For analysis of IL-8 secretion, HT-29 cell monolayers were infected for 3 h before being incubated for 8-12 h in media supplemented with 50 µg ml -1 gentamicin with or without 20 ng ml -1 TNF (Calbiochem, EMD4Biosciences). Following this, the HT-29 cell supernatant was collected and either used immediately or stored at −20°C for subsequent analysis of IL-8 secretion. IL-8 secretion was measured using the human IL-8 ELISA MAX Deluxe Set (Biolegend) according to the manufacturer's instructions.
qRT-PCR. Samples for qRT-PCR experiments were DNAse-treated using Ambion TURBO DNA-free kit and cDNA synthesis was completed using the iScript cDNA synthesis kit (Bio-Rad). qRT-PCR was performed using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) according to the manufacturer's instructions, and the gene-specific primers used are listed in Supplementary Table 1. Samples were loaded onto MicroAmp Optical 384-well reaction plates (Life Technologies) in duplicate and run on an ABI Quant Studio 7 according to the manufacturer's instructions. Melting curve analysis was used to ensure there were no primer dimers. Negative controls included both a no-reverse transcriptase control and a no cDNA control. Data were analysed by the threshold cycle method (ΔΔCt method) 38 and normalized to 18S abundance. All data are represented as fold induction relative to gene expression in uninduced, unstimulated cells or uninfected, unstimulated cells. All experiments were carried out in triplicate.
β-Lactamase translocation assay. HeLa cells were seeded in black 96-well trays with transparent well bottoms (Greiner Bio-One) for 16-24 h before infection. On the day of infection, EPEC strains with derivatives of pCX340 were cultured as previously described. Probenecid (2.5 mM, Sigma) and 1 mM IPTG (Sigma) were added to bacterial cultures for the last 45 min before infection. HeLa cells were loaded with CCF2/AM substrate following the manufacturer's instructions (Invitrogen) and incubated at room temperature in the dark for 1 h. At 15 min before infection, cells were transferred back to 37°C 5% CO 2 . Infection was carried out using 50 µl of bacterial culture with an OD 600 of 0.1 for 60 min at 37°C in 5% CO 2 . Translocation was measured as a ratio of emission 450nm :emission 520nm using a CLARIOstar Omega microplate reader (BMGLabtech) using triplicate wells for each strain.
Dual-luciferase reporter assay. For the NF-κB dual-luciferase assay, HeLa cells were seeded into 24-well trays (Corning) and co-transfected with derivatives of p3xFlag-Myc-CMV-24 (0.4 µg), 0.05 µg pRL-TK (Promega) and 0.2 µg pNF-κB-Luc (Clontech). Approximately 24 h post-transfection, cells were left untreated or stimulated with 20 ng ml -1 TNF (Calbiochem) for 6 h. Firefly and Renilla luciferase levels were measured using the dual-luciferase reporter assay system (Promega) in a CLARIOstar Omega microplate reader (BMGLabtech). The expression of firefly luciferase was normalized for Renilla luciferase measurements, and luciferase activity was expressed relative to unstimulated p3xFlag-Myc-CMV-24-transfected cells.
In vitro cleavage assays. Purified proteins were diluted out of urea-containing buffer and incubated in 100 µl reaction buffer (25 mM NaH 2 PO 4 , 150 mM NaCl, 0.5 mM DTT, pH 7.4) at a concentration of 20 µM (RHIM proteins) or 0.9 µM (EspL/EspL C47S ) for 1 h at 37°C. Sample buffer was then added to incubated proteins, before the samples were boiled and subjected to SDS-PAGE on Nu-PAGE 4-12% bis-tris polyacrylamide gels. The gels were stained with Coomassie blue stain and imaged with a GelMax imager (UVP, Analytik Jena).
To compare the cleavage of RHIM-containing protein in monomeric and fibrillar forms, 10 µg EspL was added to 200 µl of 20 µM His-Ub-RIPK3 in 25 mM NaH 2 PO 4 , 150 mM NaCl, 0.5 mM DTT, pH 7.4 immediately following dilution of His-Ub-RIPK3 from 8 M urea-containing buffer or after incubation of the diluted His-Ub-RIPK3 for 225 min at 37°C to allow fibril formation. Samples were subsequently incubated with EspL at 37°C for 1 h. For both 'monomer' and 'fibril' samples, 100 µl was pelleted at 16,000g for 10 min. The supernatant was collected as the soluble fraction and the pellet was resuspended with 100 µl of 8 M urea, pH 4.0. Samples were subjected to SDS-PAGE and stained with Coomassie blue stain for visualization and imaging as above.
Thioflavin-T assays. Thioflavin-T (ThT) assays were used to monitor fibril formation. Recombinant RHIM (20 µM) containing His-Ub-RIPK3 was incubated in buffer (25 mM NaH 2 PO 4 , 150 mM NaCl, 0.5 mM DTT, pH 7.4, 40 µM ThT) in a Costar 96-well plate (Corning) at 37°C for 3.75 h inside a POLARstar Omega microplate reader (BMGLabtech). Samples were excited at 440 nm and ThT fluorescence emission was measured at 480 nm every 60 s. Fibril formation was evident after 225 min. To test the cleavage of RHIM fibrils by EspL, 500 µl of 20 µM His-Ub-RIPK3 was dialysed against 1 l dialysis buffer (25 mM NaH 2 PO 4 , 150 mM NaCl, 0.5 mM DTT, pH 7.4) for 24 h at room temperature. 'Fibril' sample (100 µl) was then incubated with 0.9 µM purified EspL, vortexed briefly and incubated at 37°C for either 1 or 2 h. For both 'monomer' and 'fibril' samples, 100 µl was pelleted at 16,000g for 10 min. The supernatant was collected as the soluble fraction and the pellet was resuspended with 100 µl of 8 M urea, pH 4.0. Samples were subjected to SDS-PAGE and stained with Coomassie blue stain for visualization and imaging as previously mentioned.
Reverse-phase (RP) HPLC. Purified RHIM proteins (200-1,000 µl) at a concentration of 20 µM were incubated with or without 0.9 µM of purified EspL for 1 h at 37°C. Proteins were then analysed by RP-HPLC using a C 8 VYDAC column running in MilliQ water containing 0.1% TFA, 10% methanol and eluted with an increasing gradient of acetonitrile. Peaks were collected and lyophilized for further analysis by N-terminal sequencing or liquid chromatography-mass spectrometry (LC-MS)/MS. N-terminal sequencing. N-terminal sequencing was performed by the Australian Proteome Analysis Facility (APAF) at Macquarie University, New South Wales, Australia.
Characterization of His 6 -Ub-RIPK3 and His 6 -Ub-TRIF cleavage products by intact mass spectrometry analysis. Characterization of RIPK3 and TRIF cleavage products by intact mass spectrometry were performed on samples prepared by in vitro cleavage assay and purified by RP-HPLC as described above.
Time-of-flight tandem mass spectrometry (TOF MS/MS). Mass measurements of the intact protein ions and ETD and CID MS/MS were performed on a high-resolution, high-mass-accuracy quadrupole time-of-flight (qTOF) mass spectrometer (maXis II UHR qTOF, Bruker Daltonics) equipped with an electrospray ion (ESI) source for the direct-infusion method. For direct-infusion experiments, a flow rate of 180 µl min -1 was provided by a syringe pump (KdScientific) using a 25 µl syringe (SGE Analytical Sciences). The following settings were applied: capillary voltage of 4.5 kV, end plate offset of 500 V, mass range of m/z 450-2,500, dry gas at 4.0 l min -1 and drying temperature of 220°C. Nano-ESI infusion was performed using HPLC fractions, which were reconstituted in 20 µl water and diluted 1:10 with 50% acetonitrile:50% water containing 1% formic acid.
Data analysis. MS and MS/MS spectra were analysed using a dedicated top-down data analysis procedure. Briefly, precursor and product ion mass spectra were summed over the infusion time in each MS and MS/MS experiment with Data Analysis software version 4.3 (Bruker Daltonics). Automatic data analysis was performed by deisotoping, keeping only the monoisotopic masses, followed by charge state deconvolution (SNAP 2 algorithm). The obtained mass list of product ions was matched on the predicted cleaved mRIPK3 sequence to determine the product ion identity and the sequence coverage using the observed mass of the precursor ion.
Necroptosis experiments. The human epithelial cell line HT-29, as well as MDFs and iBMDMs, either infected with derivatives of EPEC E2348/69 or engineered to express EspL derivatives, were used to examine the effect of EspL on necroptosis. Necroptosis was induced by treatment with (1) 20 ng ml -1 TNF, 500 nM Cp.A and 25 µM z-VAD-FMK or 50 µM QVD-OPH, (2) 20 ng ml -1 LPS (E. coli 0111:B4) and 10 µM z-VAD-FMK or (3) 50 µg ml -1 poly(I:C) (for iBMDMs) or 10 µg ml -1 highmolecular-weight poly(I:C) (for HT-29) and 10 µM z-VAD-FMK. Cell viability was assessed by reduction of MTT or by PI uptake. MLKL complex formation and membrane translocation were examined by BN-PAGE of cell membrane and cytosolic fractions and immunoblotting using antibodies to MLKL and phospho-MLKL.
Mouse infection studies. All animal experimentation was approved by the Melbourne University Animal Ethics Committee. All mice used were of a C57BL/6 background and were age-matched as best as possible between five and eight weeks pre-infection. No calculation was used to assess the number of animals required. Male and female mice were allocated to experimental groups to ensure an even distribution of age, sex and weight, and investigators were not blinded to the allocation. C. rodentium was cultured in LB broth overnight before centrifugation and re-suspension in PBS to a concentration of ∼5 × 10 9 cells per ml. C57BL/6 mice (five to eight weeks old) were inoculated by oral gavage with 200 µl of approximately 1 × 10 9 colony-forming units c.f.u of C. rodentium. The viable count of the inoculum was determined retrospectively by plating dilutions of the inoculum on plates with appropriate antibiotics. Mice were weighed every two days, and faeces collected every two or four days for enumeration of c.f.u. The viable count per gram of faeces was determined by plating serial dilutions of faeces onto media containing selective antibiotics.
Statistical analysis. All statistical analyses were performed using GraphPad Prism version 6.0. The statistical tests used were an unpaired two-tailed Student's t-test for pairwise comparisons between groups or one-way analysis of variance (ANOVA) with Holm-Sidak's test for multiple comparisons, as indicated. Variance was similar in all comparisons. Differences in faecal counts of Citrobacter rodentium (CR) from mice, and diarrhoea and pathology scores, were assessed using a Mann-Whitney U test, where a normal distribution was not assumed. P < 0.05 was considered to be significant. Data availability. The data that support the findings of this study are available from the corresponding author upon request.
